STEEPLE bleeding criteria: Difference between revisions
No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}} | {{CMG}} | ||
==Criteria== | ==Steeple Bleeding Criteria== | ||
{{cquote| | {{cquote| | ||
Safety And Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation | Safety And Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation | ||
<ref name="pmid19171853">{{cite journal| author=Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al.| title=Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. | journal=Circulation | year= 2009 | volume= 119 | issue= 5 | pages= 680-6 | pmid=19171853 | doi=10.1161/CIRCULATIONAHA.108.803528 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19171853 }} </ref> | <ref name="pmid19171853">{{cite journal| author=Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J et al.| title=Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial. | journal=Circulation | year= 2009 | volume= 119 | issue= 5 | pages= 680-6 | pmid=19171853 | doi=10.1161/CIRCULATIONAHA.108.803528 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19171853 }} </ref> | ||
*'''Major | *'''Major Bleeding''' | ||
Fatal bleeding | Fatal bleeding | ||
Retroperitoneal, intracranial, or intraocular bleeding | Retroperitoneal, intracranial, or intraocular bleeding | ||
Line 29: | Line 28: | ||
== References == | == References == | ||
{{Reflist}} | {{Reflist}} | ||
[[Category:primary care]] | |||
[[Category:Medical emergencies]] | [[Category:Medical emergencies]] | ||
[[Category:Blood]] | [[Category:Blood]] | ||
[[Category:Hematology]] | [[Category:Hematology]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Revision as of 17:26, 27 March 2013
Bleeding Microchapters |
Treatment |
---|
Reversal of Anticoagulation and Antiplatelet in Active Bleed |
Perioperative Bleeding |
STEEPLE bleeding criteria On the Web |
American Roentgen Ray Society Images of STEEPLE bleeding criteria |
Risk calculators and risk factors for STEEPLE bleeding criteria |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Steeple Bleeding Criteria
“ |
Safety And Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation [1]
Fatal bleeding Retroperitoneal, intracranial, or intraocular bleeding Bleeding that causes hemodynamic compromise requiring specific treatment Bleeding that requires intervention (surgical or endoscopic) or decompression of a closed space to stop or control the event Clinically overt bleeding, requiring any transfusion of ≥1 U PRBC or whole blood Clinically overt bleeding, causing a decrease in hemoglobin of ≥3 g/dL (or, if hemoglobin level is not available, a decrease in hematocrit of ≥10%)
Gross hematuria not associated with trauma (eg, from instrumentation) Epistaxis that is prolonged, is repeated, or requires plugging or intervention Gastrointestinal hemorrhage Hemoptysis Subconjunctival hemorrhage Hematoma >5 cm or leading to prolonged or new hospitalization Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL Uncontrolled bleeding requiring protamine sulfate administration Safety And Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation |
” |
References
- ↑ Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J; et al. (2009). "Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial". Circulation. 119 (5): 680–6. doi:10.1161/CIRCULATIONAHA.108.803528. PMID 19171853.